2. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011; 103:368-383.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005; 55:74-108.
4. Saudi Cancer Registry cancer incidence and survival reports Saudi Arabia 2007. National Saudi Cancer Registry. Riyadh (KSA): Ministry of Health. Available at: http://www.scr.org.sa/reports/ SCR2007.pdf Website last visited Feb 2 nd, 2014.
5. Elhakeem HA, Al-Ghamdi AS, Al-Maghrabi JA. Cytopathological pattern of cervical Pap smear according to the Bethesda system in Southwestern Saudi Arabia. Saudi Med J 2005; 26:588-592.
6. Abdullah LS. Pattern of abnormal Pap smears in developing countries: A report from a large referral hospital in Saudi Arabia using the revised 2001 Bethesda System. Ann Saudi Med 2007; 27:268-272.
7. Altaf FJ. Cervical cancer screening with pattern of pap smear. Saudi Med J 2006; 27:1498-1502.
8. Balaha MH, Al Moghannum MS, Al Ghowinem N, Al Omran S. Cytological pattern of cervical Papanicolaou smear in eastern region of Saudi Arabia. J Cytol 2011; 28:173-177.
9. Makoha FW, Raheem MA. Gynecological cancer incidence in a hospital population in Saudi Arabia: the effect of foreign immigration over two decades. J Obstet Gynaecol Res 2008; 34:538-542.
10. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006; 24:11-25.
11. Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ 2009; 339:b2968.
12. Solomon D, Davey D, Kurman R. The forum group members. The Bethesda 2001 workshop. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 2002; 287:2114-2119.
13. Altaf FJ, Mufti ST. Pattern of cervical smear abnormalities using the revised. Bethesda system in a tertiary care hospital in Western Saudi Arabia .Saudi Med J 2012; 33:634-639.
14. Al-Jaroudi D, Hussain TZ. Prevalence of abnormal cervical cytology among subfertile Saudi women. Ann Saudi Med 2010; 30:397-400.
15. Ahmed A. Spectrum of cervical epithelial cell abnormalities diagnosed at King Fahd Hospital of the University, Al-Khobar, Saudi Arabia. Gomal J Med Sci 2012; 10:172-127.
16. Ghazal Aswad S, Gargash H, Badrinath P, Al-Sharhan MA, Sidky I, Osman N, et al. Cervical smear abnormalities in the United Arab Emirates: a pilot study in the Arabian Gulf. Acta Cytol 2006; 50:41-47.
17. Kapila K, George SS, Al-Shaheen A, Al-Ottibi MS, Pathan SK, Sheikh ZA, et al. Changing spectrum of squamous cell abnormalities observed on papanicolaou smears in Mubarak Al- Kabeer Hospital, Kuwait. Med Princ Pract 2006; 15:253-259.
18. Abul el-All HS, Refaat A, Dandash K. Prevalence of cervical neoplastic lesions and Human Papilloma Virus infection in Egypt: National Cervical Cancer Screening Project. Infect Agent Cancer 2007; 2:12.
19. Banik U, Bhattacharjee P, Ahamad SU, Rahman Z. Pattern of epithelial cell abnormality in Pap smear: A clinicopathological and demographic correlation. Cytojournal 2011; 8:8.
20. Bal MS, Goyal R, Suri AK, Mohi MK .Detection of abnormal cervical cytology in Papanicolaou smears. J Cytol 2012; 29:45-47.
21. Bukhari MH, Saba K, Qamar S, Majeed MM, Niazi S, Naeem S. Clinicopathological importance of Papanicolaou smears for the diagnosis of premalignant and malignant lesions of the cervix. J Cytol 2012; 29:20-25.
22. Cox JT. Management of women with cervical cytology interpreted as ASC-US or as ASC-H .Obstet Gynecol 2005; 48:160-77.
23. Adams M, B Jasani, A Fiander. HPV prophylactic vaccination: Challenges for public health and implications for screening.Vaccine 2007;25:3007-3013.
24. Bin H, Ruifang W, Ruizhen L, Yiheng L, Zhihong L, Juan l, et al. Detention of HPV L1 Capsid Protein and hTERC Gene in Screening of Cervical Cancer. Iran J Basic Med Sci 2013; 16:797–802.
25. Amarin Z O, Badria LF, Obeidat BR. Attitudes and beliefs about cervical smear testing in ever married Jordanian women. East Mediterr Health J 2008; 14:389-397.
26. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States .J Natl Cancer Inst 2009; 101:475– 487.
27. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357:1589-1597.
28. Abdoli A, Soleimanjahi H, Fotouhi F, Teimoori A, Pour Beiranvand S, Kianmehr Z. Human Papillomavirus Type16- L1 VLP Production in Insect Cells. Iran J Basic Med Sci 2013; 16:891–895.
29. Nayereh KG, Khadem G . Preventive and therapeutic vaccines against human Papillomaviruses Associated Cervical Cancers Iran. Iran J Basic Med Sci 2012; 15:585-601.
30. Nascimento AF, Cibas ES. The ASC/SIL ratio for cytopathologists as a quality control measure: a follow-up study. Am J Clin Pathol 2007; 128:653-656.
31. Thrall MJ, Pambuccian SE, Stelow EB, McKeon DM, Miller L, Savik K, et al. Impact of the more restrictive definition of atypical squamous cells introduced by the 2001 Bethesda System on the sensitivity and specificity of the Papanicolaou test: a 5-year follow-up study of Papanicolaou tests originally interpreted as ASCUS, reclassified according to Bethesda 2001 criteria. Cancer 2008; 114:171-179.